terminus, we hypothesized that PS-positive red cells (PS +ve -RBCs) bind to this domain.
We demonstrate that both heparin and its low-molecular-weight derivative enoxaparin 
1,2
It has been well recognized that PS exposure on the cell surface serves as a signal for phagocytic recognition and removal of apoptotic cells.
3
It can also function as an adhesion ligand mediating cell-cell interaction.
PS-mediated erythrocyte adhesion to endothelial cells and/or subendothelial matrix components has been documented in patients with many hemolytic anemias including sickle cell disease (SCD), 4 malaria, 5 and uremia 6 with documented positive correlation in SCD between the levels of percent PS-positivity and red cellendothelial adhesion. 4 Abnormal erythrocyte adhesion appears to play an important role in vascular complications seen not only in patients with SCD, 7 but also in malaria 5 and uremia. 6 PS-dependent erythrocyte adhesion appears to be mediated in part via thrombospondin (TSP), 8 a multifunctional and a matricellular glycoprotein. 9-13 TSP is synthesized and released by a variety of mammalian cells including endothelial cells, and is incorporated into their matrix, becoming exposed following endothelial injury or cell retraction induced by agonists such as thrombin. 14- 17 As shown in Figure-1 , while TSP can interact with a variety of cells via specific cell-binding domains on the molecule, 9-13 the binding site for the anionic PS on the TSP molecule has not been identified to date. In this study, we demonstrate that PS-positive erythrocytes bind to both soluble and immobilized TSP via its heparin-binding domain.
MATERIALS and METHODS

Materials:
Purified thrombospondin-1 from human platelets (referred to as TSP in this manuscript), annexin-V-pure (product A9460) and unfractionated heparin (from porcine intestine) were purchased from Sigma Chemical (St Louis, MO 
22,23
Preparation of PS-positive Red Cells: For the majority of experiments, PS positive HbAA erythrocytes were generated artificially from fresh adult control blood.
PS-positive red cells were prepared by treating control erythrocytes with A23187,
24,25
which routinely yielded a red cell preparation with PS positivity in the range of 60 to 75%. The ionophore-activated erythrocytes were suspended to a final concentration of Comparison between controls and paired treatment groups (effects of GAGs and TSP peptides on red cell adhesion to TSP, erythrocyte adhesion to TSP peptides, and adhesion marker levels on control verses ionophore-activated erythrocytes) was performed using the paired student t-test or the Mann-Whitney rank sum test on the medians, if the data showed non-normal distribution. Unpaired student t-test or the Mann-Whitney rank sum test was employed to compare the differences in levels of adhesion markers between high PS and low PS groups. Multiple group comparison (dose response effects with heparin and enoxaparin, and effects of TSP antibodies and divalent cations on PS-TSP adhesion) was performed using either one-way ANOVA (for data with normal distribution) or the Kruskal-Wallis test (for data with non-normal distribution). If the P-value for this overall comparison was significant at P<0.05, then group-wise comparison was performed using the Dunnett's or the Dunn's test. These erythrocytes were divided into two experimental groups including low versus high PS-positive sickle erythrocytes (1.1±0.5% versus 6.6±1.7% PS positivity, P<0.001, 
RESULTS
Binding of PS-positive Erythrocyte to
Identification of Adhesion Molecules on Erythrocytes:
Since multiple adhesion molecules are involved in mediating red cell adhesion to the components of sub-endothelial matrix, it was necessary to identify whether the other relevant adhesion molecules present on ionophore-activated erythrocytes were significantly altered. As depicted in Table- 1, among the adhesion molecules evaluated only PS showed differences on the ionophore activated control erythrocytes. We also compared adhesion marker profiles between high PS and low PS expressing SCD groups and 15 demonstrate that the differences in adhesion marker expression was confined only to PS-positivity (Table-1) .
DISCUSSION
Previous studies from our laboratories and others have documented a role for PS-positive red cells in erythrocyte-endothelial adhesion with data suggesting that adhesion was in part due to the PS-positive erythrocyte-TSP interaction. The PSbinding site on TSP has not been characterized to date. In this study using a dynamic flow adhesion assay and artificially generated PS-positive erythrocytes, we demonstrate that PS-positive erythrocytes bind to both immobilized and soluble thrombospondin via its heparin-binding domain located at the amino-terminus of the polypeptide. We show that the binding is PS specific and requires the presence of both divalent cations Ca TSP is a homotrimeric 450-kDa protein, and as shown in Figure-1 , each TSP subunit contains five distinct cell-binding domains, which interact with select protein(s), adhesion marker(s) or receptor(s).
9-13
The heparin-binding domain which is located at the amino-terminus of the polypeptide interacts with heparin, heparansulfate proteoglycans, sulfatides, and β1-integrins.
10-12
The WSPWS sequence, present within the type-I repeats, also interacts with heparansulfate proteoglycans. 10, 11 The CSVTCG motif that occurs twice within the type-I repeats binds to sulfatides, and CD36.
10,11
The integrin-binding motif, RGDS, found in the last type-III repeat interacts with the fibrinogen receptor αIIbβ3, and the vitronectin receptor αVβ3.
10,11,13
The RFYVVM sequence located at the carboxy-terminal of the polypeptide binds to CD47. produced by the latter anti-TSP antibody with sickle erythrocytes (a mean inhibition of 38%) was, however, smaller compared to that noted with artificially generated PSpositive erythrocytes (a mean inhibition of ~80%), which could be due to the differences in adhesion markers expressed on these cells as shown in Table- and sulfatides. 28 To exclude an ancillary role for these latter adhesion molecules in PS-TSP adhesion, we first elected to use un-activated and ionophore-activated control HbAA erythrocytes where, as shown in Table- 1, ionophore treatment did not alter the expression of other adhesion molecules except causing PS-positivity i.e. the ideal condition for our proposed experiments related to PS-TSP adhesion. In addition, pretreatment of TSP with an antibody that recognizes the CD47-binding domain on TSP had no effect on ionophore-activated erythrocyte adhesion (Figure-4A ). Further, while it is not known whether erythrocyte activation with A23187 perturbs membrane sulfatide composition, pretreatment of immobilized TSP with bovine brain sulfatide had no effect on A23187-treated red cell binding (Figure-3C ). it is interesting to note that previous studies in patients with SCD documented the presence of platelet-erythrocyte and neutrophil-erythrocyte aggreagates.
45-47
Previous studies have evaluated the effects of several anionic polysaccharides including heparin, CSA and HDS on sickle erythrocyte adhesion to both immobilized matrix and soluble TSP and found differential inhibitory effects, 18,28,31,44 in contrast to inhibition of a similar magnitude noted in this study with artificially generated PS-positive erythrocytes. These differences could be due to polysaccharides' ability to recognize multiple GAG binding domains on TSP, as previously documented with CSA, which in addition to its interaction with the heparin binding domain, can also bind to regions within the type-I repeats and also to regions in the carboxy-terminal cell binding domain. 48 Heparin has been used clinically as an anti-coagulant and anti-thrombotic agent.
49
Major clinical concerns of prolonged heparin therapy, however, include heparin-induced thrombocytopenia, and abnormal bleeding. To overcome these adverse clinical effects of unfractionated heparin, several low molecular weight heparin derivatives have been developed, which have numerous advantages over unfractionated preparations including clinical safety and efficacy. 50 In the present study we tested the effects on adhesion of heparin and enoxaparin, a low molecular weight
heparin derivative, and demonstrate that both these polysaccharides inhibited PSmediated erythrocyte adhesion to immobilized TSP not only at pharmacologic concentrations (5 to 50 U/ml) but also at levels (0.5 U/ml) achievable clinically in patients.
49,51
Other investigators have demonstrated that heparin can inhibit soluble TSP-, 18,31 and P-selectin-30 mediated sickle erythrocyte adhesion to cultured human endothelial cells. In addition, a previous study has suggested that prophylactic heparin therapy reduced the frequency of vaso-occlusive pain in patients with SCD.
52
Our results taken together with those previously published demonstrate that heparin can modulate multiple red cell adhesion pathways in patients with SCD and suggests that heparin and its low molecular weight derivatives may be useful as potential therapeutic agents targeting the enhanced pro-adhesive state in this patient group.
In summary, we have demonstrated that PS-positive erythrocytes bind to both 
